In last trading session, Compass Therapeutics Inc (NASDAQ:CMPX) saw 1.07 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $3.38 trading at $0.21 or 6.62% at ring of the bell on the day assigns it a market valuation of $465.05M. That closing price of CMPX’s stock is at a discount of -20.71% from its 52-week high price of $4.08 and is indicating a premium of 77.51% from its 52-week low price of $0.76.
For Compass Therapeutics Inc (CMPX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 2 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.09 in the current quarter.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Upright in the green during last session for gaining 6.62%, in the last five days CMPX remained trading in the red while hitting it’s week-highest on Thursday, 02/13/25 when the stock touched $3.38 price level, adding 12.21% to its value on the day. Compass Therapeutics Inc’s shares saw a change of 133.10% in year-to-date performance and have moved -7.40% in past 5-day. Compass Therapeutics Inc (NASDAQ:CMPX) showed a performance of 30.00% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 32.4% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -47.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -47.93% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -6.73% while estimates for its earnings growth in next 5 years are of -11.99%.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
ORBIMED ADVISORS LLC is the top institutional holder at CMPX for having 22.36 million shares of worth $22.36 million. And as of 2024-06-30, it was holding 16.2534 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0893 of outstanding shares, having a total worth of $11.13 million.
On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.73 shares of worth $9.22 million or 5.24% of the total outstanding shares. The later fund manager was in possession of 2.19 shares on Sep 30, 2024 , making its stake of worth around $7.41 million in the company or a holder of 4.20% of company’s stock.
